FINWIRES · TerminalLIVE
FINWIRES

NYK Line's Attributable Profit Declines 56% in Fiscal Year 2025

By

Nippon Yusen Kabushiki Kaisha (TYO:9101), d/b/a NYK Line, said profit attributable to owners of the parent plunged 56% to 211.75 billion yen for fiscal year 2025 from 477.71 billion yen a year earlier.

The shipping company's basic earnings per share declined to 504.85 yen from 1,070.32 yen a year ago, according to a Tokyo bourse filing on Monday.

Revenue fell to 2.424 trillion yen for the year ended March 31 from 2.589 trillion yen in the prior year.

In a separate disclosure, NYK Line raised its final dividend to 115 yen per share, payable from June 18, compared with its 110 yen forecast and year-ago payout of 195 yen.

For fiscal year 2026, the company expects attributable profit of 195 billion yen, profit per share of 464.91 yen, and revenue of 2.605 trillion yen. NYK Line plans to pay per-share interim and year-end dividends of 100 yen each, which in total is lower than the 230 yen for fiscal year 2025.

Related Articles

Asia

Shenzhen LDROBOT Soars 103% in Hong Kong Trading Debut

Shenzhen LDROBOT's (HKG:1236) shares opened 102.9% above their initial public offering price in a stellar Hong Kong debut on Monday morning.The Chinese robotics company opened at HK$53.50 per share, well above the offer price of HK$26.36.

HKG:1236
Asia

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

HKG:1093HKG:2453
Asia

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

Alterity Therapeutics (ASX:ATH) said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided "objective evidence of target engagement."The peer-reviewed publication validates the company's approach and "reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA," Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.

ASX:ATH